Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 8/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17594685 | 0.81 | HTR6 (0.40) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL4677149 | 0.81 | BRD4 (0.38) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL21695809 | 0.78 | PDE3B (0.33) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL25130119 | 0.77 | PDE3B (0.32) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL17200509 | 0.77 | BRD4 (0.37) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL17213595 | 0.77 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL16834268 | 0.77 | ALDH1A1 (0.41) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL17200464 | 0.75 | BRD4 (0.38) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL4483899 | 0.73 | PDK2 (0.38) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL30659408 | 0.73 | PDK2 (0.38) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083559-B1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-03-10 | — | — | EP | disclosed |
| US-9822107-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160340351-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2016-11-24 | — | — | US | disclosed |
| EP-3083559-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015095445-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340351-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, BTK, TYRO3 | KDM4E 1029/4885ALDH1A1 4010/4885SMN1; SMN2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.